Golcadomide

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

LymphomaFollicular LymphomaNon-Hodgkin LymphomaLarge B-Cell LymphomaRelapsed/refractory Non-Hodgkin Lymphoma

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

1

Golcadomide

Bristol-Myers Squibb

Phase 3

52

Blenoxane

SSequus Pharmaceuticals

Preclinical

253

Oncaspar

SServier

Preclinical

154

Velban

EEastern Cooperative Oncology Group

Preclinical

155

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

46

Tafasitamab

Incyte

Preclinical

77

Nuvigil

NNuvo Research GmbH

Preclinical

18

Kenalog

BBausch Health Americas, Inc.

Preclinical

19

Systemic Therapy

Bristol-Myers Squibb

Preclinical

110

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—Show 23 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Lymphoma5 trials

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Recruiting·MMayo Clinic·Phase 2·NCT06834373·41 enrolled

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

Recruiting·TThe Lymphoma Academic Research Organisation·Phase 1/2·NCT07018752·49 enrolled

Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy

Not yet recruiting·NNatalie Galanina·Phase 1/2·NCT06767956·30 enrolled

Show 2 more trials

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Recruiting·TThe Lymphoma Academic Research Organisation·Phase 2·NCT06271057·65 enrolled

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

Recruiting·NNathan Denlinger·Phase 1·NCT06209619·18 enrolled

Follicular Lymphoma3 trials

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Recruiting·Bristol-Myers Squibb·Phase 3·NCT06911502·400 enrolled

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Active, not recruiting·Bristol-Myers Squibb·Phase 2·NCT06425302·90 enrolled

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.

Active, not recruiting·OOlivia Newton-John Cancer Research Institute·Phase 2·NCT05788081·40 enrolled

Drug1 trial

A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants

Completed·Bristol-Myers Squibb·Phase 1·NCT06363630·35 enrolled

Non-Hodgkin Lymphoma1 trial

A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma

Recruiting·Roche·Phase 1·NCT05169515·121 enrolled

Large B-cell Lymphoma1 trial

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

Active, not recruiting·Bristol-Myers Squibb·Phase 3·NCT06356129·850 enrolled

1 more indication

Relapsed/Refractory Non-Hodgkin Lymphoma1 trial

A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)

Recruiting·Bristol-Myers Squibb·Preclinical·NCT06090539·460 enrolled

Details

Drug Info

Related News